Dualyx

Dualyx is a biotechnology startup that is pioneering the development of next-generation immune modulators. These are essentially drugs that can manipulate the immune system, specifically by expanding regulatory T cells (Tregs) in the body. Tregs are a type of white blood cell that can suppress autoimmune reactions, which are harmful responses where the body attacks its own cells. By increasing the number of Tregs, Dualyx's drugs could potentially provide long-lasting or even curative treatments for patients with autoimmune diseases.

Dualyx's business model revolves around the development and commercialization of these immune modulators. They have a pipeline of multi-specific antibodies, which are proteins designed to target and activate Tregs without affecting other immune cells. This selective action could lead to effective immune suppression with minimal side effects, offering a significant advantage over traditional therapeutics.

Dualyx's lead program, DT-001, is currently in the investigational new drug (IND) enabling studies stage. This drug targets the TNF receptor 2 (TNFR2), a protein that plays a key role in immune suppression and is highly expressed on Tregs. Preliminary results suggest that DT-001 could be effective in treating a wide range of autoimmune diseases.

Dualyx operates in the biotechnology and healthcare markets, serving patients with autoimmune diseases. They collaborate with industry and academic partners, such as argenx, Wurzburg University, KU Leuven, and VIB, to develop their pipeline.

In terms of revenue, Dualyx likely makes money through partnerships, grants, and potentially future sales of their drugs once they are approved and commercialized.

Keywords: Biotechnology, Immune Modulators, Autoimmune Diseases, Regulatory T Cells, Antibody Engineering, Drug Development, Healthcare, TNF Receptor 2, IND Enabling Studies, Therapeutics.